CGEN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 112971 min ago

@ $2.22

Išleistas: 14 vas. 2024 @ 16:33

Grąža: -2.70%

Ankstesnis signalas: vas. 13 - 22:01

Ankstesnis signalas: Pirkimas

Grąža: 1.14 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe...

Stats
Šios dienos apimtis	553 299
Vidutinė apimtis	498 013
Rinkos kapitalizacija	193.39M
EPS	$0 ( 2024-03-05 )
Kita pelno data	( $-0.100 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.29
ATR14	$0.00600 (0.28%)

Tūris Koreliacija

Ilgas: 0.35 (neutral)

Trumpas: 0.91 (very strong)

Signal:(57.577) Expect same movement, but be aware

Compugen Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ENTG	0.933
ADSE	0.932
KOPN	0.93
CTIC	0.926
RMBL	0.917
ALR	0.916
MVIS	0.914
MRAM	0.913
ORGO	0.912
NWLI	0.912

10 Labiausiai neigiamai susiję koreliacijos
ULTA	-0.945
ASO	-0.925
SBNYP	-0.915
TTCF	-0.889
OPTN	-0.888
CDAK	-0.884
CPRX	-0.88
PHCF	-0.87
BNIXU	-0.87
FANH	-0.869

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Compugen Ltd Koreliacija - Valiuta/Žaliavos

-0.37
( neutral )

-0.34
( neutral )

0.00
( neutral )

-0.40
( neutral )

0.15
( neutral )

0.32
( neutral )

Compugen Ltd Finansinės ataskaitos

Annual	2023
Pajamos:	$33.46M
Bruto pelnas:	$30.98M (92.59 %)
EPS:	$-0.210

FY	2023
Pajamos:	$33.46M
Bruto pelnas:	$30.98M (92.59 %)
EPS:	$-0.210

FY	2022
Pajamos:	$7.50M
Bruto pelnas:	$6.53M (87.00 %)
EPS:	$-0.390

FY	2021
Pajamos:	$6.00M
Bruto pelnas:	$5.32M (88.67 %)
EPS:	$-0.410

Financial Reports:

No articles found.

Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.